HK1149710A1 - A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant - Google Patents

A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant

Info

Publication number
HK1149710A1
HK1149710A1 HK11103923.3A HK11103923A HK1149710A1 HK 1149710 A1 HK1149710 A1 HK 1149710A1 HK 11103923 A HK11103923 A HK 11103923A HK 1149710 A1 HK1149710 A1 HK 1149710A1
Authority
HK
Hong Kong
Prior art keywords
lipopeptide
adjuvant
poly
vaccine composition
powerful vaccine
Prior art date
Application number
HK11103923.3A
Other languages
English (en)
Inventor
Hong Mo Moon
Byung Cheol Ahn
Jung Sun Yum
Original Assignee
Dobeel Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dobeel Co Ltd filed Critical Dobeel Co Ltd
Publication of HK1149710A1 publication Critical patent/HK1149710A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK11103923.3A 2007-12-07 2011-04-19 A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant HK1149710A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070126775A KR100900837B1 (ko) 2007-12-07 2007-12-07 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
PCT/KR2008/006842 WO2009072767A2 (en) 2007-12-07 2008-11-20 A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant

Publications (1)

Publication Number Publication Date
HK1149710A1 true HK1149710A1 (en) 2011-10-14

Family

ID=40718329

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103923.3A HK1149710A1 (en) 2007-12-07 2011-04-19 A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant

Country Status (9)

Country Link
US (1) US8216595B2 (xx)
EP (1) EP2214705B1 (xx)
JP (1) JP5485165B2 (xx)
KR (1) KR100900837B1 (xx)
CN (1) CN101883585B (xx)
AU (1) AU2008332196B2 (xx)
CA (1) CA2706101C (xx)
HK (1) HK1149710A1 (xx)
WO (1) WO2009072767A2 (xx)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299140A1 (en) * 2002-05-24 2008-12-04 The Regents Of The University Of California, Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition
ES2531142T3 (es) 2005-10-17 2015-03-11 Sloan Kettering Inst Cancer Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
JP5539649B2 (ja) 2005-12-13 2014-07-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞移植のための足場
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US8466259B2 (en) 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
US8287880B2 (en) 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
US8658176B2 (en) 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
WO2011014871A1 (en) 2009-07-31 2011-02-03 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
LT2624873T (lt) 2010-10-06 2020-03-10 President And Fellows Of Harvard College Įšvirkščiami, poras sudarantys hidrogeliai, skirti medžiagų pagrindo ląstelių terapijai
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2701745B1 (en) 2011-04-28 2018-07-11 President and Fellows of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
BR112014007927B1 (pt) 2011-10-06 2021-04-13 Immunovaccine Technologies Inc Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições
JP6282598B2 (ja) 2012-01-13 2018-02-21 メモリアル スローン ケタリング キャンサー センター 免疫原性ｗｔ１ペプチド及びその使用方法
AU2013249366B2 (en) 2012-04-16 2018-02-01 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
CN102949717A (zh) * 2012-07-06 2013-03-06 中国疾病预防控制中心病毒病预防控制所 一种含poly I:C佐剂的新型乙肝疫苗制剂
TWI672149B (zh) * 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
KR101669142B1 (ko) 2012-10-10 2016-10-25 연세대학교 산학협력단 안약형 백신의 신규 아쥬반트
HUE052541T2 (hu) 2013-01-15 2021-05-28 Memorial Sloan Kettering Cancer Center Immunogén WT-1 peptidek és eljárások azok alkalmazására
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
KR101501583B1 (ko) * 2013-03-29 2015-03-12 주식회사 차백신연구소 리포펩티드 및 폴리(ｉ:ｃ)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
CN104208670B (zh) * 2014-09-09 2017-07-28 韩自勤 一种治疗乙肝的药物组合物
CA3116265A1 (en) 2014-10-07 2016-04-14 Cytlimic Inc. Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
JP2018509384A (ja) 2015-01-06 2018-04-05 イミューノヴァクシーン テクノロジーズ インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． リピドａ模倣体、調製方法、及びその使用
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
ES2805829T3 (es) 2015-03-09 2021-02-15 Cytlimic Inc Péptido derivado de GPC3, composición farmacéutica para el tratamiento o la prevención de cáncer usando el mismo, inductor de inmunidad y método para producir células presentadoras de antígeno
EP3281641B1 (en) 2015-04-07 2020-12-16 Cytlimic Inc. Adjuvant for cancer vaccines
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
EP3377099A4 (en) 2015-11-18 2019-07-24 ImmunoVaccine Technologies Inc. ADJUVANT SYSTEMS AND WATER-FREE VAPOR COMPOSITION OF ONE POLYI: C-POLYNUCLEOTIDADJUVANS AND ADJUVANS ON LIPID BASE
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
RU2759728C2 (ru) 2016-10-11 2021-11-17 Ситлимик Инк. Лекарственное средство
CN107261136B (zh) * 2017-07-31 2020-07-28 中国医学科学院医学生物学研究所 多聚磷酸钠的应用及含有多聚磷酸钠的疫苗剂
KR102098097B1 (ko) * 2017-08-16 2020-05-26 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
CN111683667A (zh) * 2017-09-12 2020-09-18 加尔文医学研究所 用于减少或关停非人哺乳动物中的泌乳的方法及其试剂
CN109793891A (zh) * 2017-11-17 2019-05-24 韩震 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法
CN109200056A (zh) * 2018-11-20 2019-01-15 苏州系统医学研究所 聚肌胞在防治胰腺炎及其相关病症中的用途
WO2021231712A1 (en) * 2020-05-15 2021-11-18 Rxcell Inc. Hypoimmunogenic cells and uses thereof in immune responses
WO2022098184A1 (ko) * 2020-11-09 2022-05-12 주식회사 차백신연구소 리포펩타이드와 폴리(i:c) 아쥬반트를 포함하는 재조합 코로나-19 백신 조성물 및 이의 용도
KR102292147B1 (ko) * 2020-11-18 2021-08-23 주식회사 차백신연구소 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트
EP4327821A1 (en) 2021-05-24 2024-02-28 Cha Vaccine Research Institute Co., Ltd Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c)
KR102375057B1 (ko) * 2021-09-29 2022-03-17 주식회사 애스톤사이언스 Hsp90 항원성 펩타이드를 포함하는 항암용 백신 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839275A (en) 1983-12-01 1989-06-13 The Jewish Hospital Circulating antigens of dirofilaria immitis, monoclonal antibodies specific therefor and methods of preparing such antibodies and detecting such antigens
US4656251A (en) 1985-01-28 1987-04-07 Mallinckrodt, Inc. Rapid separation of Dirofilaria immitis immune complexes
ZW8893A1 (en) 1992-07-21 1994-06-01 Pitman Moore Inc Vaccines
GB9322702D0 (en) 1993-11-03 1993-12-22 Agricultural & Food Res Vaccines
CA2182178A1 (en) 1994-03-25 1995-10-05 David Patrick Knox Vaccines against helminthic parasites
US6399077B1 (en) 1996-08-09 2002-06-04 Trustees Of Dartmouth College Method of augmenting T cell-mediated immunity against Toxoplasma gondii
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
WO2004060319A2 (en) * 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
AU2003290460A1 (en) * 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
US8178102B2 (en) 2005-01-19 2012-05-15 Dainippon Sumitomo Pharma Co., Ltd. Emulsified composition for dilution and cancer vaccine composition
AU2006229549B2 (en) * 2005-03-31 2011-04-07 Leiden University Medical Center Methods and means for diagnostics, prevention and treatment of Mycobacterium infections and tuberculosis disease
MX2007015639A (es) * 2005-06-08 2008-02-15 Newbiomed Pika Pte Ltd Adyuvante basado en acido poliinosinico-acido policitidilico.
JP4828189B2 (ja) * 2005-09-14 2011-11-30 雅美 森山 分泌型ＩｇＡ及びＩｇＧ抗体誘導剤
US7438916B2 (en) 2005-10-14 2008-10-21 Virginia Tech Intellectual Properties, Inc. Therapeutic target for protozoal diseases
EP2316483A1 (en) * 2005-12-01 2011-05-04 The Provost Fellows And Scholars Of The College Of The Holy and Undivided Trinity Of Queen Elizabeth Near Dublin Compositions and methods relating to the treatment of cancer and infectious diseases
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법

Also Published As

Publication number Publication date
US20090155308A1 (en) 2009-06-18
CN101883585B (zh) 2013-04-17
CN101883585A (zh) 2010-11-10
WO2009072767A3 (en) 2009-07-23
EP2214705A2 (en) 2010-08-11
US8216595B2 (en) 2012-07-10
WO2009072767A2 (en) 2009-06-11
EP2214705B1 (en) 2014-08-20
JP2011506309A (ja) 2011-03-03
JP5485165B2 (ja) 2014-05-07
EP2214705A4 (en) 2011-11-30
KR100900837B1 (ko) 2009-06-04
AU2008332196B2 (en) 2011-09-15
CA2706101A1 (en) 2009-06-11
AU2008332196A1 (en) 2009-06-11
CA2706101C (en) 2014-06-03

Similar Documents

Publication Publication Date Title
HK1149710A1 (en) A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant
EP1988918A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
ZA200808489B (en) Nicotine-carrier vaccine formulation
ZA201203709B (en) Immunogenic compositions and methods
HK1144787A1 (en) Anti-fmd vaccine composition and preparation and use thereof
IL203899A (en) Foxm1-derived peptide compounds
IL209027A0 (en) Vaccine compositions and uses thereof
GB0810869D0 (en) Vaccine adjuvant composition
EP2416801A4 (en) IMMUNOGENIC COMPOSITION AND ITS USES
EP2162460A4 (en) VACCINES AGAINST CHLAMYDIA INFECTIONS
EP2207567A4 (en) IMMUNOGENIC FORMULATIONS
HK1138786A1 (en) Prophylactic tuberculosis vaccine
EP2334332A4 (en) NEW COMPOSITIONS AND NEW ADJUVANTS
GB0823497D0 (en) Immunogenic composition and use thereof
GB0805356D0 (en) Vaccine adjuvant composition
ZA200902155B (en) IPV-DPT vaccine
EP2252326A4 (en) VACCINE COMPOSITIONS
GB0818065D0 (en) Immunogenic peptides and uses thereof
EP2054081A4 (en) VACCINE AGAINST THE JC VIRUS
EP2337847A4 (en) ADJUVANTS FOR VACCINES
GB0617602D0 (en) Vaccine
TWI346557B (en) Adjuvant and vaccine includes the same
GB0606856D0 (en) Vaccine compositions
GB0801122D0 (en) Vaccine composition
GB0625593D0 (en) Vaccine